Category: Peer-reviewed

Corrigendum

With apologies from the authors of “Preterm Birth and Later Retinal Detachment: A Population-Based Cohort Study of More than 3 Million Children and Young Adults” (Ophthalmology 2013;120:2278-2285), the 6th paragraph on the 2nd column (p. 2280) shou…

Reply

We appreciate the interest and comments on our article. The spectral-domain optical coherence tomography (SD OCT) scan image from a 64-year-old woman in Figure 2 might be similar to adult-onset vitelliform dystrophy. However, the final diagnosis was m…

Reply

We appreciate Dr Kishore’s interest in our recently published manuscript. He questioned the use of bevacizumab (1.25 mg/0.05 mL; Avastin; Genentech Inc, San Francisco, California, USA) for the treatment of subfoveal hemorrhage secondary to retinal arte…

Reporting Visual Acuities

The AJO encourages authors to report the visual acuity in the manuscript using the same nomenclature that was used in gathering the data provided they were recorded in one of the methods listed here. This table of equivalent visual acuities is provided…

Author reply – Corrected Proof

We are pleased to receive comments regarding our manuscript reporting transsynaptic retrograde degeneration (TRD) of retinal ganglion cells after infarction in various areas of the brain. We measured retinal nerve fiber layer (RNFL) thickness to indire…

Polymorphisms in Vascular Endothelial Growth Factor Receptor 2 Are Associated with Better Response Rates to Ranibizumab Treatment in Age-related Macular Degeneration – Corrected Proof

Purpose: Intravitreal anti–vascular endothelial growth factor (VEGF) injections are currently the standard treatment for neovascular age-related macular degeneration (AMD), but a broad range of response rates has been observed. We evaluated the assoc…